DE69326395T2 - Spirooxathiolan-quinuclidin-Derivat zur Behandlung des Sjögren-Syndroms - Google Patents

Spirooxathiolan-quinuclidin-Derivat zur Behandlung des Sjögren-Syndroms

Info

Publication number
DE69326395T2
DE69326395T2 DE69326395T DE69326395T DE69326395T2 DE 69326395 T2 DE69326395 T2 DE 69326395T2 DE 69326395 T DE69326395 T DE 69326395T DE 69326395 T DE69326395 T DE 69326395T DE 69326395 T2 DE69326395 T2 DE 69326395T2
Authority
DE
Germany
Prior art keywords
quinuclidine
syndrome
oxathiolane
methylspiro
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69326395T
Other languages
German (de)
English (en)
Other versions
DE69326395D1 (de
Inventor
Nobuaki Abe
Yasuyoshi Takeshita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Snow Brand Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16540522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69326395(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd
Application granted granted Critical
Publication of DE69326395D1 publication Critical patent/DE69326395D1/de
Publication of DE69326395T2 publication Critical patent/DE69326395T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69326395T 1992-07-10 1993-07-09 Spirooxathiolan-quinuclidin-Derivat zur Behandlung des Sjögren-Syndroms Expired - Lifetime DE69326395T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4207485A JP2683783B2 (ja) 1992-07-10 1992-07-10 シェーグレン症候群治療剤

Publications (2)

Publication Number Publication Date
DE69326395D1 DE69326395D1 (de) 1999-10-21
DE69326395T2 true DE69326395T2 (de) 2000-04-20

Family

ID=16540522

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69326395T Expired - Lifetime DE69326395T2 (de) 1992-07-10 1993-07-09 Spirooxathiolan-quinuclidin-Derivat zur Behandlung des Sjögren-Syndroms

Country Status (15)

Country Link
US (1) US5340821A (enExample)
EP (1) EP0578511B1 (enExample)
JP (1) JP2683783B2 (enExample)
KR (1) KR100331046B1 (enExample)
AT (1) ATE184483T1 (enExample)
AU (1) AU666734B2 (enExample)
CA (1) CA2099970C (enExample)
DE (1) DE69326395T2 (enExample)
DK (1) DK0578511T3 (enExample)
ES (1) ES2138613T3 (enExample)
IL (1) IL106218A (enExample)
NO (1) NO303765B1 (enExample)
NZ (1) NZ248099A (enExample)
TW (1) TW230750B (enExample)
ZA (1) ZA934883B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2852608B2 (ja) * 1994-06-27 1999-02-03 雪印乳業株式会社 口腔乾燥症治療剤
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
JP4447685B2 (ja) * 1999-01-14 2010-04-07 第一三共株式会社 皮膚乾燥症治療剤
JP2006070027A (ja) * 2004-08-06 2006-03-16 Dai Ichi Seiyaku Co Ltd 口腔粘膜投与剤
WO2006013914A1 (ja) * 2004-08-06 2006-02-09 Daiichi Pharmaceutical Co., Ltd. 口腔粘膜投与剤
BRPI0516468A (pt) * 2004-10-05 2008-09-09 Astellas Pharma Inc composição farmacêutica para o tratamento de xeroftalmia e xerostomia
AU2006282896A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8143400B2 (en) * 2008-01-10 2012-03-27 Apotex Pharmachem Inc. Process for the preparation and purification of cis-2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine hydrochloride
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
SI2498771T1 (sl) 2009-11-12 2014-04-30 Acacia Pharma Limited Uporaba betanekola za zdravljenje kserostomije
GB201107533D0 (en) 2011-05-06 2011-06-22 Acacia Pharma Ltd Formulaiton
CN102846607A (zh) * 2012-04-09 2013-01-02 珠海亿邦制药股份有限公司 一种以盐酸西维美林为活性成分的固体制剂及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001396A (en) * 1971-08-04 1977-01-04 Chinoin Pharmaceutical And Chemical Works Ltd. Hormonal product extracted from parathyroid gland and process for the preparation thereof
US4110441A (en) * 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US4684727A (en) * 1985-07-29 1987-08-04 Schering Corporation Zwitterionic 1,8-naphthyridine and pyrazino[2,3-b]pyridine containing compounds useful as anti-allergic, anti-inflammatory and cycloprotective agents
ZA868369B (en) * 1986-01-10 1987-11-25 Israel State Derivatives of quinuclidine
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US4876260A (en) * 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
CA1303503C (en) * 1987-11-10 1992-06-16 Marc Plamondon Ophthalmic solution comprising iodine-polyvinylpyrrolidone complex
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US4997654A (en) * 1989-08-14 1991-03-05 Warner-Lambert Company Method for increasing salivation for xerostomia patients
DE69220258T2 (de) * 1991-02-11 1997-12-18 Merck Sharp & Dohme Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung

Also Published As

Publication number Publication date
US5340821A (en) 1994-08-23
NO932520L (no) 1994-01-11
TW230750B (enExample) 1994-09-21
NO303765B1 (no) 1998-08-31
IL106218A0 (en) 1993-11-15
DK0578511T3 (da) 2000-04-03
AU4181993A (en) 1994-01-13
DE69326395D1 (de) 1999-10-21
CA2099970C (en) 2003-12-30
AU666734B2 (en) 1996-02-22
JPH0624981A (ja) 1994-02-01
NO932520D0 (no) 1993-07-09
KR100331046B1 (ko) 2002-08-19
EP0578511A1 (en) 1994-01-12
CA2099970A1 (en) 1994-01-11
KR940005274A (ko) 1994-03-21
IL106218A (en) 1997-02-18
ES2138613T3 (es) 2000-01-16
ZA934883B (en) 1994-02-03
NZ248099A (en) 1999-07-29
EP0578511B1 (en) 1999-09-15
ATE184483T1 (de) 1999-10-15
JP2683783B2 (ja) 1997-12-03

Similar Documents

Publication Publication Date Title
DE69326395T2 (de) Spirooxathiolan-quinuclidin-Derivat zur Behandlung des Sjögren-Syndroms
DE69630479T2 (de) Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten
DE3788984T2 (de) Verwendung von Prostaglandin-D2-aktiven-Substanzen zur Behandlung von Augen-Hypertension und von Glaukom.
DE69636308T2 (de) Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
DE69522511T2 (de) Spirooxathiolan-quinuclidin-Derivat zur Behandlung von Xerostomie
DE69934813T2 (de) Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen
DE3786893T2 (de) Piperidinderivat zur Schmerzbehandlung.
DE3639378C2 (enExample)
DE3390114T1 (de) Verbesserte analgetische und antiinflammatorische, Ibuprofen enthaltende Zubereitungen und Verfahren zu ihrer Herstellung
DE3511609C2 (enExample)
CZ355897A3 (cs) Způsob léčení mánie a bipolárních poruch
DE10043282A1 (de) Verwendung von Inhibitoren der Amyloid-beta-Protein-Bildung
DE69226487T2 (de) Verwendung von Furanonderivaten zur Vorbeugung oder Behandlung von Autoimmunkrankheiten
DE69907387T2 (de) Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von refraktärer Vasculitis.
DE69003670T2 (de) Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs.
DE69115528T2 (de) Neue pharmazeutische Verwendungen von Forskolin-Derivaten
DE3873210T2 (de) Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz.
DE69200365T2 (de) Pharmazeutische Zusammensetzung zur Verbesserung von Dysuria.
EP0331871B1 (de) Antipsychotisch wirksames Imidazobenzodiazepin
DE69903546T2 (de) Levosimendan für die behandlung von pulmonaler hypertonie
DE60035177T2 (de) Arzneimittel für trockene haut
DE3781339T2 (de) Therapeutisches mittel fuer gastritis.
DE2823268C2 (enExample)
DE69219219T2 (de) Verwendung von 3-Pyridazinone zur Verringerung der Blutplätchenzahl
DE3887426T2 (de) Eperisone als Hypotonikum.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DAIICHI PHARMACEUTICAL CO., LTD., TOKIO/TOKYO, JP

8328 Change in the person/name/address of the agent

Representative=s name: BOETERS & LIECK, 81541 MUENCHEN

8327 Change in the person/name/address of the patent owner

Owner name: DAIICHI SANKYO CO., LTD., TOKYO, JP